CIPLA
NSECIPLA LTD
Healthcare / Pharma
CIPLA LTD clears only 1 of 3 checks. The numbers flag real concerns — exactly the kind of thing that gets lost in exciting news or social-media buzz. Tread carefully.
The four quality checks
Every company faces the same four checks. Tap the ? on any term to learn what it means.
Is the company drowning in loans?
We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.
The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.
Does it make good money, consistently?
We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.
Profits relative to the money invested are on the weaker side over the last few years.
Is the big, smart money buying in?
Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.
Big investors are roughly holding their position, neither rushing in nor out.
Is the price reasonable right now?
Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.
We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.
What we noticed
Observations from the data — not recommendations.
- Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]
StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.